Overview

Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Treadwell Therapeutics, Inc
Collaborator:
TIO Discovery Engine
Treatments:
Pembrolizumab